UBS Group AG Has $22.30 Million Stock Holdings in Spyre Therapeutics, Inc. $SYRE

UBS Group AG lifted its position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) by 76.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 680,566 shares of the company’s stock after purchasing an additional 294,977 shares during the period. UBS Group AG’s holdings in Spyre Therapeutics were worth $22,295,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Russell Investments Group Ltd. raised its holdings in Spyre Therapeutics by 2,881.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after buying an additional 4,092 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Spyre Therapeutics by 182.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock valued at $86,000 after acquiring an additional 3,725 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Spyre Therapeutics by 61.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,770 shares of the company’s stock valued at $124,000 after acquiring an additional 1,435 shares during the period. Man Group plc bought a new position in shares of Spyre Therapeutics during the second quarter valued at $162,000. Finally, Profund Advisors LLC lifted its holdings in shares of Spyre Therapeutics by 19.7% during the third quarter. Profund Advisors LLC now owns 13,223 shares of the company’s stock worth $222,000 after purchasing an additional 2,180 shares during the period. Institutional investors and hedge funds own 80.39% of the company’s stock.

Spyre Therapeutics Stock Up 1.9%

Shares of NASDAQ SYRE opened at $76.43 on Tuesday. The company has a market capitalization of $6.64 billion, a PE ratio of -36.75 and a beta of 3.12. Spyre Therapeutics, Inc. has a twelve month low of $13.93 and a twelve month high of $78.80. The firm has a fifty day simple moving average of $54.76 and a 200 day simple moving average of $39.40.

Spyre Therapeutics (NASDAQ:SYRE) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.08). As a group, equities analysts expect that Spyre Therapeutics, Inc. will post -2.75 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Michael Thomas Henderson sold 80,000 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $74.40, for a total transaction of $5,952,000.00. Following the transaction, the director owned 88,606 shares of the company’s stock, valued at $6,592,286.40. This represents a 47.45% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott L. Burrows sold 12,500 shares of the stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $71.37, for a total value of $892,125.00. Following the completion of the transaction, the chief financial officer owned 97,994 shares in the company, valued at approximately $6,993,831.78. The trade was a 11.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 233,791 shares of company stock worth $15,757,860 in the last quarter. 15.69% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

SYRE has been the topic of several analyst reports. Wells Fargo & Company boosted their price objective on shares of Spyre Therapeutics from $50.00 to $90.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 14th. Deutsche Bank Aktiengesellschaft lifted their target price on Spyre Therapeutics from $55.00 to $88.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Wedbush increased their price target on Spyre Therapeutics from $65.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, April 13th. Stifel Nicolaus raised their price objective on Spyre Therapeutics from $92.00 to $107.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Finally, Robert W. Baird lifted their price objective on Spyre Therapeutics from $65.00 to $90.00 and gave the stock an “outperform” rating in a research note on Tuesday, April 14th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Spyre Therapeutics has an average rating of “Buy” and an average price target of $89.08.

Spyre Therapeutics Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.